<div id="readability-page-1"><div><p>Teladoc Health (TDOC) opened 2026 with Q1 revenue of US$613.8 million and a basic EPS loss of US$0.36, alongside a trailing twelve month EPS loss of US$0.96 on revenue of US$2.5 billion. Over recent quarters, the company has seen revenue move from US$629.4 million in Q1 2025 to US$613.8 million in Q1 2026, while quarterly EPS shifted from a loss of US$0.53 to a loss of US$0.36 as net income moved from a loss of US$93.0 million to a loss of US$63.8 million. This keeps the focus firmly on how quickly margins can tighten and losses can shrink from here.</p> <p>See our full analysis for Teladoc Health.</p><p>With the latest results on the table, the next step is to set these margin trends against the most common Teladoc Health narratives to see which stories the numbers support and which they call into question.</p> <p>See what the community is saying about Teladoc Health</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2058b889-8ca4-41d5-85c2-037212a7c328/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTAx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2058b889-8ca4-41d5-85c2-037212a7c328/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTAx"/><figcaption>NYSE:TDOC Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Losses easing on a trailing basis</h2> <ul> <li>On a trailing 12 month view, net loss narrowed from US$200.3 million at Q4 2025 to US$171.1 million at Q1 2026, and basic EPS loss improved from US$1.14 to US$0.96 over the same period.</li> <li>Supporters of the bullish view point to this pattern of shrinking losses, arguing it lines up with the longer term 32.2% annual loss reduction and the idea that Teladoc can move toward better margins even while revenue growth sits at 1.7% a year.     <ul> <li>That said, quarterly net loss in Q1 2026 at US$63.8 million is wider than Q4 2025 at US$25.1 million, which challenges a straight line bullish story and shows the path has been uneven.</li> <li>The bullish narrative expects profit margins to eventually turn positive, but the trailing numbers still show an unprofitable business, so the data partly supports and partly questions how quickly that margin shift can happen.</li> </ul> </li> </ul> <p>Recent loss trends and the mixed quarterly pattern are exactly what bullish investors debate when they argue Teladoc is on the cusp of a more profitable phase, so if that angle interests you it is worth seeing how those arguments are laid out in full <strong>🐂 Teladoc Health Bull Case</strong></p> <h2>Flat revenue trend with modest 1.7% growth</h2> <ul> <li>Reported revenue over the last six quarters has moved in a fairly tight band between US$613.8 million and US$642.3 million, which lines up with the 1.7% annual growth rate on a trailing 12 month basis and sits well below the cited 11% wider US market growth rate.</li> <li>Bears focus on this modest top line pace, arguing that a roughly flat revenue run rate combined with ongoing losses makes it harder for Teladoc to offset rising compliance, data privacy, and reimbursement costs that are highlighted in the cautious narrative.     <ul> <li>The Q1 2026 revenue figure of US$613.8 million is lower than Q4 2025 at US$642.3 million, which fits with the bearish concern that growth could stall if competition and reimbursement pressures bite.</li> <li>At the same time, revenue has not collapsed, and the trailing 12 month total of about US$2.5b shows the business still has scale, so the data challenges the idea that the addressable opportunity is already capped.</li> </ul> </li> </ul> <p>For readers weighing whether these revenue patterns back up the more cautious arguments about Teladoc's business mix and competitive position, it can help to see how skeptics frame the risks in more detail <strong>🐻 Teladoc Health Bear Case</strong></p> <h2>Low 0.4x P/S against DCF fair value</h2> <ul> <li>Teladoc trades on a P/S of 0.4x versus peer and industry averages of 2.2x and 2.1x, and the stated DCF fair value of US$11.68 sits well above the current share price of US$6.06, even though analysts expect the company to remain unprofitable over the next three years.</li> <li>Supportive investors highlight this valuation gap, arguing that the combination of a 48.1% discount to DCF fair value and loss reduction over five years makes the current multiple look conservative, while more cautious voices question how long the market will wait for profitability when revenue growth is running at just 1.7% a year.     <ul> <li>The consensus analyst price target of US$7.10 is only modestly above the current share price, which contrasts with the much larger gap to the DCF fair value and shows that not all valuation frameworks are pointing to the same level of upside.</li> <li>The P/S discount to peers comes alongside continued losses of US$171.1 million on a trailing 12 month basis, so the low multiple is linked directly to the unprofitable status rather than clear evidence of mispricing.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Teladoc Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>After weighing the mixed signals in Teladoc's results and valuation, it makes sense to move quickly, review the data yourself, and check how the balance of concerns and potential rewards stacks up for your own portfolio using the 3 key rewards and 1 important warning sign</p> <h2>Explore Alternatives</h2> <p>Teladoc Health is still reporting losses alongside modest 1.7% annual revenue growth, which raises questions about how efficiently its scale is translating into profitability.</p> <p>If that mix of ongoing losses and only gradual top line progress feels uncomfortable, it is worth quickly comparing with companies screened for stronger value and quality profiles via the 51 high quality undervalued stocks</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Teladoc Health might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

TDOC

<p>Teladoc Health reported Q1 2026 revenue of $613.8 million with a basic EPS loss of $0.36, showing a slight decline from Q1 2025. Despite a reduction in net losses, concerns remain about flat revenue growth of 1.7% and rising costs. The company's P/S ratio of 0.4x is significantly lower than industry averages, raising questions about its profitability timeline. Analysts have a consensus price target of $7.10, indicating limited upside potential compared to its DCF fair value of $11.68. Investors are divided on the company's future profitability and growth prospects.</p>

Teladoc Health Q1 Loss Reduction Reinforces Bullish Margin Narrative Despite Flat Revenue